参附注射液对脓毒性休克患者舌下微循环的影响:一项随机对照试验
本研究为前瞻性、单中心、随机、双盲、安慰剂对照临床试验,纳入脓毒性休克患者40例,随机分为参附注射液组(n=20)和安慰剂组(n=20),分别接受参附注射液或葡萄糖注射液治疗5天。结果显示,参附注射液组舌下微循环总血管密度、灌注血管密度和微血管流动指数显著增加,内皮功能障碍生物标志物Ang-2、Syn-1和ET-1水平逆转,APACHE-II评分、SOFA评分、血管活性药使用时间和EICU住院时间均优于对照组。但28天死亡率参附注射液组为15%(3/20),安慰剂组为25%(5/20),差异无统计学意义(P=0.693)。作者认为参附注射液改善舌下微循环灌注的保护作用可能与抑制内皮功能障碍和血管舒张效应有关。
要点
- 参附注射液组舌下微循环总血管密度、灌注血管密度和微血管流动指数较安慰剂组显著增加,微循环障碍明显减轻。
- 参附注射液组内皮功能障碍生物标志物Ang-2、Syn-1和ET-1水平较安慰剂组逆转。
- 参附注射液组APACHE-II评分、SOFA评分、血管活性药使用时间和EICU住院时间均优于安慰剂组。
- 28天死亡率参附注射液组15%(3/20) vs 安慰剂组25%(5/20),差异无统计学意义(P=0.693)。
适用人群与场景
- 脓毒性休克患者,来自急诊重症监护病房(EICU),随机分为参附注射液组(n=20)和安慰剂组(n=20)。
处置流程与药物剂量
- 参附注射液组接受参附注射液治疗5天,安慰剂组接受葡萄糖注射液治疗5天;采用避光输液设备隐藏治疗分配,对研究者和临床工作人员设盲。
研究设计与关键结果
- 研究类型:前瞻性、单中心、随机、双盲、安慰剂对照临床试验;样本量40例(参附注射液组n=20,安慰剂组n=20);人群为脓毒性休克患者。
- 干预与对照:参附注射液 vs 葡萄糖注射液,均治疗5天。
- 主要终点结果:参附注射液组舌下微循环总血管密度、灌注血管密度和微血管流动指数显著增加,微循环障碍明显减轻;血浆内皮功能障碍生物标志物Ang-2、Syn-1和ET-1水平逆转。
- 关键次要终点:参附注射液组APACHE-II评分、SOFA评分、血管活性药使用时间和EICU住院时间均优于安慰剂组。
- 28天死亡率:参附注射液组15%(3/20) vs 安慰剂组25%(5/20),差异无统计学意义(P=0.693)。
证据类型、等级与局限
- 证据类型:随机对照试验(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,参附注射液改善脓毒性休克患者舌下微循环灌注的保护作用可能与抑制内皮功能障碍和血管舒张效应有关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background and Objective: The optimization of macrocirculatory hemodynamics is recommended by current sepsis guidelines. However, microcirculatory dysfunction is considered the cause of severe sepsis. In the present study, we designed to verify whether the application of Shenfu injection (SFI) restores microcirculation, thereby improving tissue perfusion and inhibiting organ dysfunction, resulting in improved outcomes. Design: We conducted a prospective, single-center, randomized, double-blind, placebo-controlled clinical trial. Intervention: Patients were randomly assigned to group receiving SFI (n = 20) or placebo (n = 20) for 5 days. We administered SFI or glucose injection for 5 days and blinded the investigators and clinical staff by applying light-proof infusion equipment that concealed therapy allocation. Measurements and Results: We measured the systemic dynamics and lactate levels, biomarkers of endothelial dysfunction, and inflammatory cytokines in the plasma. The parameters of sublingual microcirculation were assessed using side-stream dark-field imaging. Sequential Organ Failure Assessment (SOFA) score, Acute Physiology and Chronic Health Evaluation (APACHE) score, total dose, and duration of vasopressor use, emergency intensive care unit (EICU) stay, and 28-day mortality were evaluated. After treatment with SFI, the disturbance of the sublingual microcirculation was considerably alleviated, as indicated by the significant increase in total vessel density, perfused vessel density, and microvascular flow index. Moreover, the plasma biomarker levels of endothelial dysfunction, including Ang-2, Syn-1, and ET-1, were reversed after SFI treatment. Importantly, the SFI group had a more favorable prognosis than the control group in terms of the APACHE-II score, SOFA score, duration of vasopressor administration, and length of EICU stay. However, the difference in mortality at day 28 was not statistically different between the SFI (15%, 3/20) and placebo (25%, 5/20) groups ( P = 0.693). Conclusions : Shenfu injection provided apparent effects in improving sublingual microcirculatory perfusion in patients with septic shock, and this protection may be related with the inhibition of endothelial dysfunction and vasodilatory effects.
参考来源
- Wang S, Liu G, Chen L, et al. EFFECTS OF SHENFU INJECTION ON SUBLINGUAL MICROCIRCULATION IN SEPTIC SHOCK PATIENTS: A RANDOMIZED CONTROLLED TRIAL. Shock. 2022. PMID: 35959775. doi:10.1097/SHK.0000000000001975
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。